MEDICINAL CHEMISTRY, cilt.17, sa.10, ss.1104-1128, 2021 (SCI-Expanded)
Background: Targeted therapies acting on specific molecular targets in cancer cells with better curative efficacy and lower toxicity have come into prominence for the management of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). COX-2 stands out as a plausible target for anticancer agents due to its pivotal role in tumor initiation, progression and invasion.